Skip to content

Johnson & Johnson JNJ Treasury Stock

Treasury Stock at other companies

Abbott logo
AbbottABT
$17.97B+8.2%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$43.52B-0.2%
Tenet Healthcare logo
Tenet HealthcareTHC
$5.26B+35.2%
Pfizer logo
PfizerPFE
$115.19B+0.2%
Procter & Gamble logo
Procter & GamblePG
$142.17B+3.0%
Merck & Co. logo
Merck & Co.MRK
$63.75B+7.3%

Other financials

Income statement

See full
Revenue$25.3B+6.6%
Gross profit$17.3B+7.1%
Operating income$7.1B+7.4%
Net income$5.5B-0.1%
EPS (diluted)$2.27-0.9%

Balance sheet

See full
Cash & equivalents$20.4B+9.9%
Total debt$49.0B-3.4%
Total equity$85.0B+8.3%
Total assets$201.06B+4.0%

Cash flow

See full
Operating cash flow$8.6B+122%
CapEx$1.3B+26.7%
Free cash flow$7.3B+157%

Valuation

See full
Market cap$634.77B+58.6%
Enterprise value$663.38B+53.4%
P/E30.2×+12.5×
P/S6.5×+2.1×

Profitability

See full
Gross margin67.9%0.0pp
Operating margin26.5%+2.8pp
Net margin21.5%-3.5pp
FCF margin22.7%+2.2pp

Returns & leverage

See full
Return on equity25.7%-4.5pp
Debt / equity0.6×-0.1×
Current ratio1.1×+0.1×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: Johnson & Johnson’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's treasury stock?
Johnson & Johnson (JNJ) reported treasury stock of $75.86B in Q2 2026.
How has Johnson & Johnson's treasury stock changed year-over-year?
Johnson & Johnson's treasury stock increased by 0.2% year-over-year, from $75.71B to $75.86B.
What is the long-term trend for Johnson & Johnson's treasury stock?
Over 3 years (2022 to 2025), Johnson & Johnson's treasury stock has grown at a 22.0% compound annual growth rate (CAGR), from $41.69B to $75.62B.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.